These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 21798073)
1. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. Fan L; He F; Liu H; Zhu J; Liu Y; Yin Z; Wang L; Guo Y; Wang Z; Yan Q; Huang G BMC Cancer; 2011 Jul; 11():320. PubMed ID: 21798073 [TBL] [Abstract][Full Text] [Related]
2. Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma. Chu X; Zhao P; Lv Y; Liu L Int J Clin Exp Pathol; 2015; 8(1):328-36. PubMed ID: 25755719 [TBL] [Abstract][Full Text] [Related]
3. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144 [TBL] [Abstract][Full Text] [Related]
4. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. Shimada M; Sugimoto K; Iwahashi S; Utsunomiya T; Morine Y; Imura S; Ikemoto T J Gastroenterol; 2010 Aug; 45(8):896-902. PubMed ID: 20379837 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451 [TBL] [Abstract][Full Text] [Related]
6. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. Wang M; Xiao J; Jiang J; Qin R Int J Cancer; 2011 Apr; 128(8):1996-7. PubMed ID: 20568110 [No Abstract] [Full Text] [Related]
7. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. Leelawat K; Thongtawee T; Narong S; Subwongcharoen S; Treepongkaruna SA World J Gastroenterol; 2011 Mar; 17(9):1192-8. PubMed ID: 21448425 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Yonglitthipagon P; Pairojkul C; Chamgramol Y; Loukas A; Mulvenna J; Bethony J; Bhudhisawasdi V; Sripa B Hum Pathol; 2012 Oct; 43(10):1719-30. PubMed ID: 22446018 [TBL] [Abstract][Full Text] [Related]
9. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Li Q; Wang JM; Liu C; Xiao BL; Lu JX; Zou SQ Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):70-5. PubMed ID: 18234642 [TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma. Xu Y; Zhu M; Zhang S; Liu H; Li T; Qin C Pathol Oncol Res; 2010 Jun; 16(2):169-75. PubMed ID: 19757198 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859 [TBL] [Abstract][Full Text] [Related]
13. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma. Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932 [TBL] [Abstract][Full Text] [Related]
14. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis. Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624 [TBL] [Abstract][Full Text] [Related]
15. Characterization of CD133+ parenchymal cells in the liver: histology and culture. Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219 [TBL] [Abstract][Full Text] [Related]
16. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030 [TBL] [Abstract][Full Text] [Related]
17. Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. Kato M; Shinozawa T; Kato S; Endo K; Terada T Liver; 2000 Jun; 20(3):216-21. PubMed ID: 10902971 [TBL] [Abstract][Full Text] [Related]
18. Loss of MTSS1 expression is an independent prognostic factor for Hilar cholangiocarcinoma. Wang F; Liu Y; Zhang H Pathol Oncol Res; 2013 Oct; 19(4):815-20. PubMed ID: 23852458 [TBL] [Abstract][Full Text] [Related]
19. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors). Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Terada T; Nakanuma Y; Sirica AE Hum Pathol; 1998 Feb; 29(2):175-80. PubMed ID: 9490278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]